Related Experiment Video

Updated: Dec 17, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K

Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5

Y-Q Zheng1, X Miao, J Li

  • 1Department of General Surgery, First Medical Center, PLA General Hospital, Beijing, China. zhangyanjun@301hospital.com.cn.

European Review for Medical and Pharmacological Sciences
|June 24, 2020
PubMed
Abstract

Insights

Histone deacetylase inhibitor Trichostatin A (TSA) suppresses breast carcinoma progression by downregulating lysophosphatidic acid receptor 5 (LPAR5). This reduces cancer cell proliferation and metastasis, offering a potential therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Breast carcinoma is a leading cause of cancer-related mortality worldwide.
  • Metastasis significantly contributes to poor patient outcomes in breast cancer.
  • Understanding the molecular mechanisms driving breast cancer metastasis is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the role of Trichostatin A (TSA) in breast carcinoma metastasis.
  • To elucidate the molecular mechanism by which TSA affects breast cancer progression.
  • To examine the relationship between lysophosphatidic acid receptor 5 (LPAR5) and breast carcinoma metastasis.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qRT-PCR) to assess LPAR5 expression in tissues and cell lines.
  • Cell proliferation assays (CCK-8), migration assays (Transwell, wound healing) to evaluate cancer cell behavior.
  • Xenograft mouse models to study the in vivo effects of TSA and LPAR5 on tumor growth.

Main Results:

  • LPAR5 was found to be upregulated in breast carcinoma tissues and associated with increased metastasis and poorer patient survival.
  • TSA treatment dose-dependently downregulated LPAR5 expression in breast cancer cell lines.
  • TSA inhibited breast cancer cell proliferation and migration, and this effect was reversed by LPAR5 overexpression in vivo.

Conclusions:

  • TSA effectively suppresses breast carcinoma cell proliferation and migration.
  • The mechanism involves the downregulation of LPAR5 by TSA.
  • Targeting LPAR5 with TSA presents a potential therapeutic avenue for managing breast cancer metastasis.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.6K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.4K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K